In a phase I study, the ORR of ivosidenib was 41.6%, the CR and CRi was 30.4%.615 In a phase 1 clinical trial, the ORR of olutasidenib was 41% and 46% in combination with azacitidine in relapsed/refractory AML.616 The ORR of enasidenib in relapsed/refractory AML patients with IDH2 mutations was 40.3%, and the CR was 19.3% in a phase I/II study.617 The median OS for all pateints was 9.3 months, but 19.7 months for patients who achieved CR. The gene discussed is IDH2; the disease is acute myeloid leukemia.